{"id":"NCT01566695","sponsor":"Celgene","briefTitle":"The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-26","primaryCompletion":"2019-01-25","completion":"2023-12-21","firstPosted":"2012-03-29","resultsPosted":"2020-02-26","lastUpdate":"2025-01-07"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Myelodysplastic Syndrome"],"interventions":[{"type":"DRUG","name":"Oral Azacitidine","otherNames":["CC-486"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Best Supportiv Care (BSC)","otherNames":[]}],"arms":[{"label":"Oral Azacitidine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Evaluation of the Efficacy and Safety of Oral Azacitidine plus Best Supportive care versus Placebo and Best Supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to International Prognostic Scoring System (IPSS) lower risk myelodysplastic syndromes (MDS).","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days","timeFrame":"Each participant was assessed for at least 56 days or more; from the date of randomization of study drug up to the data cut-off date of 25 January 2019, approximately 5 months.","effectByArm":[{"arm":"Oral Azacitidine and Best Supportive Care","deltaMin":30.8,"sd":null},{"arm":"Placebo Plus Best Supportive Care","deltaMin":11.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":196,"countries":["United States","Australia","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Israel","Italy","Mexico","Netherlands","Norway","Poland","Portugal","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["27148452","33764805"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsclinicaltrials.com/us/en/home"]},"adverseEventsSummary":{"seriousAny":{"events":83,"n":107},"commonTop":["Nausea","Diarrhoea","Vomiting","Constipation","Neutropenia"]}}